Welcome To Yuehua Mao's C.V.

Yuehua Mao M.D.

Department of Pathology
Columbia University
630 west 168th St., VC15-204
New York, NY 10032
E-mail: [email protected]





TITLE:

  • Technologist

EDUCATION:

  • M.S. Molecular Biology, Hunter College of CUNY, NY, U.S.A. May 1999.
  • M.S. Virology & Immunology. Shanghai Medical College of Fudan University, Shanghai, China, 1989.
  • M.D. Medicine XiangYa School of Medicine, CSU, Changsha, China, 1983.

Summary:

  • I am currently a Technologist at Columbia University in New York, working in Flow lab. Performing immunotyping for lymphoma / leukemia, T cell panel and CD34; My previous research focuses on gene therapy and gene regulation for lung cancer, pancreatic cancer and breast cancer. I have a strong background in molecular and cell biology. I combine an expertise on research, innovation, attention to detail and approachability.

Skills & Expertise:

  • Set up machine eveyday, run BD FACSDiva CS&T and 7-color bits • compensation, skill at Diva and Canto sofware, Manipulate template and Data analysis with FCS Express software • multi-parameter flow cytometry to analyze of cell markes of cancer cell • FACS analysis to analyze drug induced apoptosis and necrosis by anexin V (FITC conjugated) and PI staining • Cell sortting to select colony cell with engineered protein expression marker on the membrane • Molecular Biology • Immunohistochemistry • Northern Blotting • Gene clone, gene modification, Plasmid Isolation • Protein Expression and Purification in yeast, insect cell and bacterial • Gene regulation: DNA methylation, gene array, RT-PCR, microRNA detection • Viral Vectors preparation • Confocal Microscopy • Fluorescence Fluorescence • ELISA • HPLC • RIA • chemiluminescent assays • Supplies and ordering • Routine equipment maintenance • Photoshop, Word, Excel, Powerpoint, computer maintenance
EXPERIENCE:
  • 2016-Present Flow lab. Department of Pathology. Columbia University, N.Y.
      Technologist
    • Performing immunotyping assay for lymphoma / leukemia
    • T cell Panel
    • CD34
    • Set up 10 color FCS Express analysis template
    • Monthly quality control
  • 2003-2016 Division of Oncology, Department of Medicine Columbia University, N.Y.
      Associate Research Scientist
    • Studing gene therapy by modified promoter which preferential expression in cancer cells with mutant p53 and mutant Ras.
    • Set up Tet-On regulated p53 C-terminal-4-repeat expresstion system.
    • Studing effect of hydroxyurea on BRCA1/BRCA2 methylation in ovarian cancer cell line
    • Studing the mechanism of GEMZAR, 5-Fu, and Taxotere on pancreatic cancer cells.
  • 1999-2003 Herbert Irving Comprehensive Cancer Center, Columbia University, N.Y.
      Post-doctoral Research Scientist
    • Sulindac Sulfide Inhibits Transcription of Cyclin D1 and Induces Apoptosis in Sw480 Human Colon Cells. Involve DNA transformation, luciferase assay and FACS analysis.
    • Studied cGMP mediated apoptosis induced by Sulindac Derivatives via activation of JNK1. Using: Caspase-3 assays, Protein Kinase assay and Northern Bloting.
    • Prepared plasmid for transfection, handled DNA transformation, Northern bloting, cell culture, PCR and Western bloting

  • 1995-1997 Lab. of Chemical Biology, NIDDK/NIH, MD.
      Post-doctoral Fellow
    • Studied the regulation of mutant hemoglobin gene expression in response to different drugs in vitro, using a micro-globin chain biosynthetic assay with HPLC, globin mRNA quantitation with RT-PCR.

  • 1990-1995 Shanghai National Institute of Medical Genetics. Shanghai, China.
      Associate Research Scientist
    • Studied the regulation of mutant hemoglobin gene expression in response to drugs in vitro and in vivo. Using proliferation and maturation of human erythroid progenitors in tissue culture, micro-globin chain biosynthetic assay with HPLC, globin mRNA quantitation with RT-PCR/primer extension, and DNA footprinting.
    • Analysis of the molecular basis of thalassemia and Hunting’s disease. Involved in DNA sequencing, Southern blotting, MASPCR, DNA cloning.

  • 1986-1990 National Lab. of Molecular Virology, Shanghai Medical University.
      Research Associate
    • Studied the effect of hepatitis B virus on interferon production in hepatocytes. Using: Isolation and purification of hepatitis B virus, preparation antibody, immunochemical assay, Western blotting, electron microscopy.

  • 1983-1986 Shanghai Institute of Biological Production.
      Research Assistant
    • Preparation of vaccine of Japanese B encephalitis virus and rabies. Using: primary cell culture, virus amplification, purification, inactivation, and concentration.
PUBLICATIONS:
  1. Robert L. Fine, Yuehua Mao, Dario Garcia-Carracedo, Gloria H. Su, Wanglong Qiu, Gwen Nichols, Yong-Liang Li, Richard D. Dinnen, Anthony Raffo, Paul W. Brandt-Rauf Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines 2023 Jan 18;11(2):258
  2. Robert L. Fine,Yuehua Mao, Richard Dinnen , Ramon V Rosal , Anthony Raffo , Uri Hochfeld , Patrick Senatus , Jeffrey N Bruce , Gwen Nichols , Hsin Wang , Yongliang Li , Paul W Brandt-Rauf C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines. 2023 Jan 5;11(1):137
  3. Yuehua Mao, Richard D Dinnen, and Robert L. Fine. Induction of BRCAness phenotype by curcumin and hydroxyurea in WT BRCA ovarian cancer cellsAmerical Association for Cancer Research Presentation April, 2014
  4. Yuehua Mao Richard D Dinnen, and Robert L Fine. Induction of BRCAness phenotype by curcumin and hydroxyurea in WT BRCA ovarian cancer cells Americal Association for Cancer Research PresentationSep, 2013
  5. Dinnen RD, Mao Y, Qiu W, Cassai N, Slavkovich VN, Nichols G, Su GH, Brandt-Rauf P, Fine RL. Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. Molecular Cancer Therapeutics 2013 Dec;12(12):2792-803
  6. Robert L. Fine, Anthony P. Gulati, Benjamin A. Krantz, Rebecca A. Moss, Stephen Schreibmam, Dawn A. Tsushima, Kelley B. Mowatt, Richard D. Dinnen, Yuehua Mao, Peter D. Stevens, Beth Schrope, John Allendorf, James A. Lee, William H. Sherman, John A. Chabot Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience Cancer Chemother Pharmacol 71(3):663, 2013
  7. Richard D. Dinnen, Yuehua Mao, Robert L. Fine . The use of fluorescent probes in the study of reactive oxygen species in pancreatic cancer cells Pancreatic Cancer Methods in Molecular Biology Volume 980, 2013, pp 321-329
  8. Xiantao Wang, Anthony J. Di Pasqua,Sudha Govind, Erin McCracken, Charles Hong, Lixin Mi, Yuehua Mao,§ Jessie Yu-Chieh Wu, York Tomita, Jordan C. Woodrick, Robert L. Fine, and Fung-Lung Chung. Selective Depletion of Mutant p53 by Cancer Chemopreventive Isothiocyanates and Their Structure-Activity Relationships J. Med. Chem. 2011, 54 (3), pp 809–816
  9. Richard D. Dinnen‡, Lisa Drew‡, Daniel P. Petrylak‡, Yuehua Mao‡, Nicholas Cassai§, Joseph Szmulewicz§, Paul Brandt-Rauf¶, and Robert L. Fine‡1 Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. J Biol Chem. 2007 Sep 14;282(37):26675-86. Epub 2007 Jul 18.
  10. yuehua Mao, Richard Dinnen, Gwen Nichols, Paul Brandt-Rauf and Robert Fine. A bi-directionally controlled, modified p14ARF promoter linked to bicistronic p14 and t-BID induces selective apoptosis only in cancer cells with mutant ras and mutant p53. AACR Meeting Oral Presentation Apr. 2007
  11. Yuehua Mao, Ramon V. Rosal, Patrick B. Senatus, Yi Li, Yongliang Li, Jeffrey N. Bruce, Paul W. Brandt-Rauf and Robert L. Fine. A C-terminal p53 palindromic tetrapeptide restores full apoptotic potential to mutant p53 cancer cell in vitro and in vivo AACR Meeting Oral Presentation, Apr. 2005
  12. Patrick B. Senatus, Yin Li, Christopher Mandigo, Gwen Nichols, Gaetan Moise, Yuehua Mao, Melandee D. Brown, Richard C. Anderson, Andrew T. Parsa, Paul W. Brandt-Rauf, Jeffrey N. Bruce and Robert L. Fine* Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide Molecular Cancer Therapeutics 5 Jan. 2006
  13. Yin Li, Yuehua Mao, Paul W. Brandt-Rauf, Ann C. Williams and Robert L. Fine* Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway Molecular Cancer Therapeutics 4 Jun. 2005
  14. Ramon Rosal, Paul Brandt-Rauf , Matthew R. Pincus, Hsin Wang,Yuehua Mao, Yin Li, Robert L. Fine,* The role of alpha-helical structure in p53 peptides as a determina for their mechanism of cell death: necrosis versus apoptosis Advanced Drug Delivery Reviews 28 Feb. 2005
  15. Li, Y., Mao, Yuehua, Ramon V. Rosal , Richard D. Dinnen , Ann C. Williams , Paul W. Brandt-Rauf , Robert L. Fine 1 Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells International Journal of Cancer 11 Jan 2005
  16. Yuehua Mao, Anthony J. Raffo, Yin Li, Richard D. Dinnen, Daniel P. Petrylak, Paul W. Brandt-Rauf and Robert L. Fine. Induction of FADD/FAS apoptosis in mutant p53 cancer cells by a palindromic C-terminal p53 peptide. American Association for Cancer Research Presentation. 2004
  17. Yin Li, Anthony J. Raffo, Lisa Drew, Mao, Yuehua, Andy Tran, Daniel P.Petrylak, and Robert L. Fine: Fas-Mediated Apoptosis Is Dependent on Wild-Type p53 Status in Human Cancer Cells Expressing a Temperature-Sensitive p53 Mutant Alanine-143. Cancer Research. 63:1527,2003.
  18. Jingqing Luo,Jae-Won Soh, Wang-Qiu Xing, Mao, Yuehua,Tetsuya Matsuno and I. Bernard Weinstein: PM-3. a Benzo-gama-pyran Derivative Isolated from Propolis, Inhibits Growth of MCF-7 Human Breast Cancer Cells. Anticancer Research. 21: 1665,2001.
  19. Jae-Won Soh, Mao, Yuehua, W.Joseph Thompson and I. Bernard Weinstein: Sulindac Sulfide inhibits Transcription of Cyclin D1 and Induces Apoptosis in SW480 Human Colon Cancer Cells. J.Biol.Chem. 276:16406,2001.
  20. Soh, J.W., Mao Yuehua, Kim, M.G., Pamukcu, R., Li, H., Piazza, G.A., Thompson, W.J., and Weinstein, I. B.: cGMP Mediates Apoptosis Induced by Sulindac Derivatives via Activation of JNK1. Clinical Cancer Research. 6:4136, 2000.
  21. Yue-Hua Mao, Min Sheng, Mei-Jue Chen, Zhao-Rui Ren, Yi-Tao Zeng, Shu-Zhen Huang: Prenatal Diagnosis of ß-Thalassemia Using Multiplex Allele-Specific Amplification (MASPCR) in Chinese Families. Hematology 1(3):253 - 257 (1996), DOI: 10.3109/10245349609163331
  22. Mao, Yuehua, Zeng Yitao: Molecular Analysis of Huntington’s Disease with Expanded CAG Trinucleotide Repeat in Chinese. Chinese J Med. Genet. 13:131, 1996.
  23. Mao, Yuehua, Zeng Yitao: Prenatal Diagnosis of beta-thalassemia Using Multiplex Allele-Specific Amplification (MASPCR). Chinese J Haemtol. 17:409,1996.
  24. Mao, Yuehua, Wen Yumei: Effect of DHBV on Interferon Production in Duck Hepatocytes. Proceedings of Conference of Hepatitis B Viruses, Cold Spring Harbor Lab., p204, 1989.Abstract
  25. Huang Shuzhen, Mao, Yuehua, Zeng Yitao: The Effect of Hydroxyurea (HU) on the Expression of beta-thalassemia Allele IVS-2-654 C->T. Chinese J. Haemtol. 18:514, 1996.
  26. Zeng Yitao, Mao, Yuehua: Molecular Diagnosis of Huntington’s Disease: an analysis of two large families. National Medical Journal of China. 75:689, 1995.
  27. Mao, Yuehua, Zeng Yitao: Direct Detection of the Expanded CAG Repeat in IT15 Gene for Molecular Diagnosis of Huntington’s Disease. High Technology Letters. 1; 4, 1995.
  28. Zeng Yitao, Chen Meijue, Mao,Yuehua: Molecular Analysis of the Hunting’s Disease with Expanded CAG Trinucleotide Repeat in Chinese. High Technology Letters (in English), 5:1, 1995.
  29. Mao,Yuehua, Huang Shuahen and Zeng Yitao: Application of Multiplex Allele-Specific Amplification for Molecular Diagnosis of beta-thalassemia. Chinese J. Med. Genet.12: 209, 1995.
  30. Mao,Yuehua, Wen Yumei: Duck Hepatocyte Culture and Induction Interferon. Chinese J. Microbio & Immuno. 11: 62, 1991.
PATENT:
  1. C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Potential to Mutant p53 Cancer Cells in Vitro and in Vivo. Patent number US7772367
  2. Gene Therapy with p14 / tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 In Vitro and in Vivo. In the process of patent. patent publication\ number W02007127165 A2
AWARDS:
  • 2006 - 2009 The Enid Goldman Postdoctoral Fellowship Award for Pancreatic Cancer Research 2006-2009, The Enid Goldman fundation
  • Award for Achievements in Scientific & Technology, Ministry of Health, P.R. China, 1996.
  • Award for Achievements in Scientific & Technology, Shanghai Municipal Government, 1995.
License:
  • Clinical Laboratory Technologist, restricted to flow cytometry/cellular immunology in the state of New York 11/06/2017
REFERENCES
  • George Vlad, PhD
  • Knosp Camille, PhD
  • Mathew Thomsen, MPH